Revance Launches the Teoxane RHA^® Collection with Mepivacaine 

The innovative filler line challenges the status quo by replacing the local anesthetic with mepivacaine. 

Teoxane, a leading player in hyaluronic acid-based dermal fillers and dermocosmetics, and Revance, a fast-growing global aesthetics and skincare company, announce the latest innovation in its aesthetic portfolio with the launch of the Teoxane RHA^® Collection with Mepivacaine.¹ 

As of today, mepivacaine will replace lidocaine as the anesthetic in the Teoxane RHA^® Collection in the U.S. market, celebrating the first major anesthetic innovation in hyaluronic acid filler in almost two decades.²

The Teoxane RHA^® Collection with Mepivacaine received FDA approval in 2023 and is exclusively patented by Teoxane for use in dermal fillers.^1,3-7 This deliberate, research-driven innovation delivers patient comfort with patient care in mind.^8-9 While new to the aesthetic market, mepivacaine has been widely used in therapeutic areas for over 60 years.¹⁰ 

Mepivacaine features the same mechanism of action as lidocaine, with less local vasodilation, reducing the potential for injection site reactions such as bruising.^9-11 
Preclinical and clinical studies comparing RHA Redensity^® with Mepivacaine to RHA Redensity^® with lidocaine, as well as RHA^® 4 with Mepivacaine to RHA^® 4 with lidocaine found similar rheology, effective pain control, established safety profile, and no change in aesthetic outcomes.^1,8,12 

“The development of the Teoxane RHA^® Collection with Mepivacaine exemplifies Teoxane’s commitment to innovation,” states Valérie Taupin, Founder and CEO of Teoxane. “Mepivacaine represents the first major advancement in pain management in fillers in nearly two decades. It provides an anesthetic effect comparable to currently available products, but with reduced local vasodilation, as demonstrated in the recent article published in RSC Pharmaceutics, 2025, which may result in less bruising. We are proud to bring this patented innovation to providers and offer great patient comfort. Teoxane is leading the way in a next-generation approach to optimal patient experience in aesthetics.” 

“It’s incredibly rewarding to help bring the next evolution of RHA^® to the U.S. market. The addition of mepivacaine reflects our commitment to advancing the patient experience without compromising the outcomes providers have come to expect from the RHA^® Collection by Teoxane. We’re proud to lead the way in innovation that matters to both patients and practices.” states Jeff Bedard, Founder and CEO, Revance. 

Learn more at https://www.revance.com/news/press-releases/teoxane-rha-collection-mepivacaine-launch